{"url_path":"/sec/avln/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1540171/0001193125-26-254581-index.html","accession_number":"0001193125-26-254581","cik":"0001540171","ticker":"AVLN","issuer_name":"Avalyn Pharma Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1540171/0001193125-26-254581-index.html","primary_entity_key":"0001540171","primary_entity_name":"Avalyn Pharma Inc."},"word_count":84,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n99.1\n\n \n\n[Press Release of Avalyn Pharma Inc. dated June 3, 2026](ck0001540171-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nAvalyn Pharma Inc.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 3, 2026\n\nBy:\n\n/s/ Lyn Baranowski\n\n \n\n \n\n \n\nLyn Baranowski\nChief Executive Officer\n(Principal Executive Officer)"}